The impact of Bifidobacterium animalis subsp. lactis HN019 probiotic in the prevention of periodontitis associated with immunosuppression.
- 2022-12-07
- Journal of Periodontology 94(3)
- Luciana Prado Mai
- Yara Loyanne de Almeida Silva Levi
- Pedro Henrique Félix Silva
- Luana Carla Wons
- Livia Pizzo Pitelli
- Jéssica Goulart de Castro
- Eder da Silva Dólens
- D. Gregório
- Fabiana Gouveia Straioto
- Carolina Dos Santos Santinoni
- R. Casarin
- E. Ervolino
- Flávia Aparecida Chaves Furlaneto
- Michel Reis Messora
- PubMed: 36245273
- DOI: 10.1002/JPER.22-0146
Abstract
Background: This study evaluated the effects of the probiotic Bifidobacterium animalis subsp. lactis HN019 (HN019) in the development of experimental periodontitis (EP) in rats submitted to chemotherapy (5-fluorouracil [5FU]).
Methods: Eighty male rats were divided into the following groups: control (C); treated with 5FU (60 mg/kg at day 30 and 40 mg/kg at day 32); treated with probiotic (HN019) (daily, for 44 days, starting at day 0); treatment with 5FU and probiotic (5FU-HN019); only EP (EP) (ligature placed on lower first molars at day 30, maintained for 14 days); EP and treatment with 5FU (EP-5FU); EP and treatment with probiotic (EP-HN019); and EP and treatment with 5FU and probiotic (EP-5FU-HN019). Euthanasia occurred at day 44. Morphometric, histomorphometric, microtomographic, immunohistochemical, immunoenzymatic, and gene expressions analyses were performed. The data obtained were statistically analyzed (p < 0.05).
Results: The EP-5FU-HN019 group showed less bone and connective tissue loss when compared with EP-5FU group, while EP-HN019 and EP-5FU-HN019 groups had greater bone volume than EP and EP-5FU groups, respectively (p < 0.05). A decrease in immunostaining for tartrate-resistant acid phosphatase and RANKL, an increase for osteoprotegerin and lower interleukin-1β levels were observed in EP-5FU-HN019 group, when compared with EP-5FU group (p < 0.0001). Probiotic therapy led to an increase in the proportions of B. lactis in the feces (p = 0.0018), but not in the biofilm, and reduced the expression of Fusobacterium nucleatum and Prevotella intermedia in the biofilm (p < 0.0001).
Conclusion: B. lactis HN019 reduced the severity of EP in rats submitted to chemotherapy, modulating immunoinflammatory parameters in periodontal tissues and reducing periodontopathogens expression on biofilm in rats submitted to chemotherapy.
Keywords: antineoplastic agents; bifidobacterium animalis; periodontitis; probiotics.
Research Insights
| Supplement | Health Outcome | Effect Type | Effect Size |
|---|---|---|---|
| Bifidobacterium animalis subsp. lactis | Increased Bone Volume | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis | Increased Osteoprotegerin Immunostaining | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis | Increased Proportion of Fecal Bifidobacterium lactis | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis | Reduced Interleukin-1β Levels | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis | Reduced Severity of Periodontitis | Beneficial | Large |
| Bifidobacterium animalis subsp. lactis BLC1 | Increased Fecal Bifidobacterium lactis Levels | Beneficial | Small |
| Bifidobacterium animalis subsp. lactis BLC1 | Reduced Periodontopathogen Biofilm Expression | Beneficial | Large |
| Bifidobacterium animalis subsp. lactis BLC1 | Reduced Severity of Periodontitis | Beneficial | Large |
| Bifidobacterium animalis subsp. lactis BS-01 | Modulated Inflammatory Response | Beneficial | Large |
| Bifidobacterium animalis subsp. lactis BS-01 | Reduced Periodontopathogen Biofilm Expression | Beneficial | Large |
| Bifidobacterium animalis subsp. lactis BS-01 | Reduced Severity of Periodontitis | Beneficial | Large |
| Bifidobacterium animalis subsp. lactis CECT 8145 | Reduced Periodontopathogens Expression | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis CECT 8145 | Reduced Severity of Periodontitis | Beneficial | Large |
| Bifidobacterium animalis subsp. lactis HN019 | Increased Bone Volume | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis HN019 | Increased Fecal Bifidobacterium lactis Levels | Beneficial | Small |
| Bifidobacterium animalis subsp. lactis HN019 | Reduced Immunoinflammatory Markers | Beneficial | Large |
| Bifidobacterium animalis subsp. lactis HN019 | Reduced Periodontopathogen Expression | Beneficial | Large |
| Bifidobacterium animalis subsp. lactis LAFTI B94 | Increased Bone Volume | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis LAFTI B94 | Increased Fecal Bifidobacterium lactis Levels | Beneficial | Small |
| Bifidobacterium animalis subsp. lactis LAFTI B94 | Increased Osteoprotegerin Expression | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis LAFTI B94 | Reduced Interleukin-1β Levels | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis VK2 | Improved Bone Volume | Beneficial | Large |
| Bifidobacterium animalis subsp. lactis VK2 | Reduced Inflammatory Responses | Beneficial | Large |
| Bifidobacterium animalis subsp. lactis VK2 | Reduced Pathogenic Load | Beneficial | Large |
| Bifidobacterium lactis BS01 | Increased Bone Volume | Beneficial | Moderate |
| Bifidobacterium lactis BS01 | Increased Fecal Bifidobacterium lactis Levels | Beneficial | Small |
| Bifidobacterium lactis BS01 | Increased Osteoprotegerin Immunostaining | Beneficial | Moderate |
| Bifidobacterium lactis BS01 | Reduced Interleukin-1β Levels | Beneficial | Moderate |
| Bifidobacterium lactis HN019 | Modulated Immunoinflammatory Parameters | Beneficial | Moderate |
| Bifidobacterium lactis HN019 | Reduced Periodontopathogen Biofilm Expression | Beneficial | Large |
| Bifidobacterium lactis HN019 | Reduced Severity of Periodontitis | Beneficial | Large |
| Bifidobacterium lactis MAK16B42L | Increased Bone Volume | Beneficial | Moderate |
| Bifidobacterium lactis MAK16B42L | Increased Fecal Bifidobacterium lactis Levels | Beneficial | Small |
| Bifidobacterium lactis MAK16B42L | Reduced Severity of Periodontitis | Beneficial | Large |
| Bifidobacterium lactis SD-5219 | Modulated Immunoinflammatory Parameters | Beneficial | Moderate |
| Bifidobacterium lactis SD-5219 | Reduced Expression of Periodontal Pathogens | Beneficial | Moderate |
| Bifidobacterium lactis SD-5219 | Reduced Severity of Periodontitis | Beneficial | Large |